ATC Group: A05AX04 Maralixibat chloride

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A05AX04 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A05 Bile and liver therapy
3 A05A Bile therapy
4 A05AX Other drugs for bile therapy
5 A05AX04

Active ingredients in A05AX04

Active Ingredient Description
Maralixibat

Maralixibat is a minimally absorbed, reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Maralixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum.

Related product monographs

Title Information Source Document Type  
LIVMARLI Oral solution European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Croatia (HR)

Estonia (EE)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Romania (RO)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.